Precision Medicine Approaches When Prostate Cancer Akts Up.

Published

Journal Article

Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.See related article by de Bono et al., p. 928.

Full Text

Duke Authors

Cited Authors

  • Zhang, T; George, DJ; Armstrong, AJ

Published Date

  • February 1, 2019

Published In

Volume / Issue

  • 25 / 3

Start / End Page

  • 901 - 903

PubMed ID

  • 30206162

Pubmed Central ID

  • 30206162

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-2491

Language

  • eng

Conference Location

  • United States